Every 10-Q that Becton, Dickinson and Co. (BDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDX filings page.
Becton, Dickinson and Company reported fiscal quarter results for the period ended March 31, 2026 that mix solid revenue growth with significant one‑time charges and a major portfolio change. Continuing operations revenues rose to $4.714 billion from $4.480 billion, driven by 2.4% volume growth and a 2.6% favorable currency impact.
Despite higher sales, BD posted a net loss of $311 million, versus net income of $308 million a year earlier, as earnings were weighed down by discontinued operations and restructuring. Loss from discontinued operations related to the spin‑off of the Biosciences and Diagnostic Solutions business was $274 million for the quarter, while integration, restructuring and transaction expense surged to $533 million, including $450 million of non‑cash asset impairments.
BD completed the spin‑off and Reverse Morris Trust combination of that business with Waters Corporation, receiving a $4 billion cash distribution. The company used $2 billion for an accelerated share repurchase and $2 billion for debt repayments, contributing to long‑term debt falling to $14.706 billion from $17.620 billion. Operating cash flow from continuing operations strengthened to $1.328 billion for the first six months, supporting $589 million of dividends and $2.250 billion of total share repurchases.
Becton Dickinson reported quarterly revenue of $5.252 billion, up slightly from $5.168 billion, with net income rising to $382 million and diluted EPS of $1.34 versus $1.04 a year earlier. Cash from operations was $657 million.
On February 9, 2026, BD spun off its Biosciences and Diagnostic Solutions business and combined it with Waters in a Reverse Morris Trust, receiving a $4 billion cash distribution. BD plans to deploy about $2 billion into an accelerated share repurchase in Q2 2026 and use the remainder mainly for debt repayment.
BD continues large legal and product-liability accruals of about $1.7 billion and recorded an $83 million liability tied to an FDA Warning Letter on its dispensing equipment operations. The company also maintains an active multi‑year share repurchase program and increased authorizations, repurchasing $250 million of stock in the quarter while paying $299 million in dividends.